Aldeyra

Lexington, United States Founded: 2004 • Age: 22 yrs
Drug candidates for immune-mediated diseases are developed by Aldeyra.
Request Access

About Aldeyra

Aldeyra is a company based in Lexington (United States) founded in 2004.. Aldeyra has raised $4.79 million across 6 funding rounds from investors including Hercules Capital, Perceptive Advisors and Sphera Fund. The company has 9 employees as of December 31, 2024. Aldeyra has completed 1 acquisition, including Helio Vision. Aldeyra offers products and services including RASP Modulator Platform and ADX-2191. Aldeyra operates in a competitive market with competitors including Annexon, Nicox, Gyroscope, MeiraGTx and Alimera Sciences, among others.

  • Headquarter Lexington, United States
  • Employees 9 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Aldeyra Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0
    0
    as on Dec 31, 2024
  • Net Profit
    $-55.85 M
    -48.77
    as on Dec 31, 2024
  • EBITDA
    $-59.87 M
    -40.76
    as on Dec 31, 2024
  • Total Equity Funding
    $4.79 M (USD)

    in 6 rounds

  • Latest Funding Round
  • Investors
  • Employee Count
    9

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Aldeyra

Aldeyra is a publicly listed company on the NASDAQ with ticker symbol ALDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: ALDX . Sector: Health technology · USA

Products & Services of Aldeyra

Aldeyra offers a comprehensive portfolio of products and services, including RASP Modulator Platform and ADX-2191. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Modulates immunological systems to inhibit inflammatory cells in diseases.

Treats signs and symptoms of dry eye disease through targeted mechanisms.

People of Aldeyra
Headcount 10-50
Employee Profiles 9
Board Members and Advisors 6
Employee Profiles
People
David Noskowitz
Vice President, Regulatory Affairs
People
Christopher Pearson
Vice President, Commercial Development and Strategy
People
Todd C. Brady
CEO & President
People
Lise L. Kjems
Vice President, Clinical Development

Unlock access to complete

Board Members and Advisors
people
Ben Bronstein
Director

Unlock access to complete

Funding Insights of Aldeyra

Aldeyra has successfully raised a total of $4.79M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round
  • First Round

    (03 Jan 2013)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2020 Amount Post-IPO - Aldeyra Valuation

investors

Mar, 2019 Amount Debt – Conventional - Aldeyra Valuation

investors

Feb, 2019 Amount Post-IPO - Aldeyra Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Aldeyra

Aldeyra has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Perceptive Advisors and Sphera Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture debt financing is provided to companies in multiple sectors.
Founded Year Domain Location
Health-tech companies are targeted for venture capital investments.
Founded Year Domain Location
Manages hedge funds with long/short equity and real estate strategies for investors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Aldeyra

Aldeyra has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Helio Vision. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Developer of small molecule based therapeutics for the treatment of eye diseases
2016
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Aldeyra

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Aldeyra Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Aldeyra

Aldeyra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Nicox, Gyroscope, MeiraGTx and Alimera Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of antibodies to treat complement-mediated neurodegenerative diseases
domain founded_year HQ Location
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
domain founded_year HQ Location
Mobile SDK developed for app engagement and monetization strategies.
domain founded_year HQ Location
Gene therapies for ocular and neurodegenerative diseases are developed.
domain founded_year HQ Location
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Aldeyra

When was Aldeyra founded?

Aldeyra was founded in 2004 and raised its 1st funding round 9 years after it was founded.

Where is Aldeyra located?

Aldeyra is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.

Is Aldeyra a funded company?

Aldeyra is a funded company, having raised a total of $4.79M across 6 funding rounds to date. The company's 1st funding round was a Post-IPO of $10M, raised on Jan 03, 2013.

How many employees does Aldeyra have?

As of Dec 31, 2024, the latest employee count at Aldeyra is 9.

What does Aldeyra do?

Aldeyra was founded in 2004 and is based in Lexington, United States. Operations are conducted in the biotechnology sector, where drug candidates are developed to address immune-mediated diseases. The pipeline targets inflammatory cells associated with ocular and systemic conditions, including Reproxalap for dry eye disease and allergic conjunctivitis, as well as ADX-2191 for proliferative vitreoretinopathy and other programs.

Who are the top competitors of Aldeyra?

Aldeyra's top competitors include Annexon, Alimera Sciences and MeiraGTx.

What products or services does Aldeyra offer?

Aldeyra offers RASP Modulator Platform and ADX-2191.

Is Aldeyra publicly traded?

Yes, Aldeyra is publicly traded on NASDAQ under the ticker symbol ALDX.

How many acquisitions has Aldeyra made?

Aldeyra has made 1 acquisition, including Helio Vision.

Who are Aldeyra's investors?

Aldeyra has 4 investors. Key investors include Hercules Capital, Perceptive Advisors, Sphera Fund, and DAFNA Capital Management.

What is Aldeyra's ticker symbol?

The ticker symbol of Aldeyra is ALDX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available